Byooviz Or Beovu? Canadian Court Halts Samsung, Biogen Biosimilar Trademark

Is Byooviz, the ranibizumab biosimilar manufactured by Samsung Bioepis and sold in Canada by Biogen, too similar in name and likely to cause confusion with another anti-VEGF treatment for serious eye disease that preceded it, Novartis’ Beovu (brolucizumab)? As such, does it violate Novartis’ trademark rights?

A Federal court in Ontario says that it does, granting injunctive relief to the Swiss originator following meticulous analysis that included a deep dive into the relevant consumers of both products and the